Tawi, Romelyn .
HRN: 22-40-07 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/28/2022
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
12/28/2022
01/03/2023
IVT
375mg
Q6
URTI
Waiting Final Action
Indication: Empiric Type of Infection: URTI Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes